[Initial experience with isophosphamide in the treatment of progressive-chronic polyarthritis].
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D001171:Arthritis, Juvenile / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D055598:Chemical Phenomena; D002621:Chemistry; D003882:Dermatomyositis / Q000188:drug therapy; D004117:Dimethoate / Q000009:adverse effects / Q000627:therapeutic use; D004357:Drug Synergism; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010488:Polyarteritis Nodosa / Q000188:drug therapy
D009943:Organophosphorus Compounds; D004117:Dimethoate; D008775:Methylprednisolone
Erste Erfahrungen mit Isophosphamid bei der Behandlung der progredient-chronischen Polyarthritis.